The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 07, 2024
Filed:
Mar. 16, 2020
Applicant:
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Inventors:
Wensheng Yu, Edison, NJ (US);
Joseph A. Kozlowski, Princeton, NJ (US);
Dane James Clausen, Rahway, NJ (US);
Jian Liu, Edison, NJ (US);
James Fells, Hillsborough, NJ (US);
Assignee:
Merck Sharp & Dohme LLC, Rahway, NJ (US);
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 471/22 (2006.01); A61K 31/426 (2006.01); A61K 31/438 (2006.01); A61K 31/4418 (2006.01); A61K 31/4439 (2006.01); A61K 31/4748 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/52 (2006.01); A61K 31/635 (2006.01); A61K 31/685 (2006.01); A61P 31/18 (2006.01); C07D 487/08 (2006.01); C07D 491/18 (2006.01); C07D 498/22 (2006.01);
U.S. Cl.
CPC ...
C07D 471/22 (2013.01); A61K 31/426 (2013.01); A61K 31/438 (2013.01); A61K 31/4418 (2013.01); A61K 31/4439 (2013.01); A61K 31/4748 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/635 (2013.01); A61K 31/685 (2013.01); A61P 31/18 (2018.01); C07D 487/08 (2013.01); C07D 491/18 (2013.01); C07D 498/22 (2013.01);
Abstract
The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.